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Background: The protein growth arrest specific-1 (GAS1) was discovered based on its ability to stop the cell cycle.
During development it is involved in embryonic patterning, inhibits cell proliferation and mediates cell death, and has
therefore been considered as a tumor suppressor. GAS1 is known to signal through two different cell membrane
receptors: Rearranged during transformation (RET), and the sonic hedgehog receptor Patched-1. Sonic Hedgehog
signalling is important in stem cell renewal and RET mediated signalling in neuronal survival. Disorders in both
sonic hedgehog and RET signalling are connected to cancer progression. The neuroprotective effect of RET is
controlled by glial cell-derived neurotrophic factor family ligands and glial cell-derived neurotrophic factor
receptor alphas (GFRαs). Human Growth arrest specific-1 is a distant homolog of the GFRαs.
Results: We have produced and purified recombinant human GAS1 protein, and confirmed that GAS1 is a monomer in
solution by static light scattering and small angle X-ray scattering analysis. The low resolution solution structure reveals
that GAS1 is more elongated and flexible than the GFRαs, and the homology modelling of the individual domains
show that they differ from GFRαs by lacking the amino acids for neurotrophic factor binding. In addition, GAS1
has an extended loop in the N-terminal domain that is conserved in vertebrates after the divergence of fishes
and amphibians.
Conclusions: We conclude that GAS1 most likely differs from GFRαs functionally, based on comparative structural
analysis, while it is able to bind the extracellular part of RET in a neurotrophic factor independent manner, although
with low affinity in solution. Our structural characterization indicates that GAS1 differs from GFRα’s significantly also in
its conformation, which probably reflects the functional differences between GAS1 and the GFRαs.
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Growth Arrest Specific-1 gene (GAS1) was found in a
screen to identify genes specifically expressed in growth-
arrested mouse cells [1]. The full-length cDNA of hu-
man GAS1 was cloned [2,3] and the mature protein was
found to contain 345 amino acids, a potential signal pep-
tide, one N-glycosylation site at Asn117 and an aminated
Ser318 [2,3]. The aminated Ser318 allows the mature
protein to be glycophosphatidylinositol (GPI) anchored
to the cell membrane [2,4].* Correspondence: tommi.kajander@helsinki.fi
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unless otherwise stated.GAS1 was found to arrest cell cycle by stopping the
cells in synthesis (S) phase [1,5] and due to its ability to
arrest cell proliferation in p53-dependent manner it has
been considered to be a tumour suppressor protein
[6,7]. Generally GAS1 might act as a tumour suppressor
in adult brain, though the expression in brain leading to
apoptosis has not been observed in adults [3,8]. Se-
quence comparison of human and murine GAS1 genes
suggested that it has a conserved RGD-peptide sequence
for possible RGD-dependent integrin binding at residues
306–308 [3].
Additionally GAS1 has been shown to have a signifi-
cant role in development [9]. At early developmental
stages GAS1 is expressed in most embryonic tissues.
During development GAS1 has been reported to inhibithis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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volved in embryonic patterning, and to support growth
of the cerebellum [3,8].
GAS1 is clearly a multifunctional protein, since it signals
through at least two different kinds of transmembrane re-
ceptor proteins, Rearranged during transformation (RET)
[8] and the Hedgehog receptor protein patched-1 [10,11].
The Hedgehog signalling pathway is important in develop-
ment, stem cell renewal, and cancer progression. GAS1 is
able to bind sonic hedgehog (SHH) and activate the sig-
nalling pathway from patched-1 [10,11]. RET, on the other
hand, is a transmembrane kinase, first identified as a
proto-oncogene [12]. Overactivity of RET can cause sev-
eral types of cancers, and loss-of-function mutations cause
varying degrees of loss in the enteric nervous system
resulting in Hirschprung’s disease (see e.g. Robertson and
Mason [13]). Normally RET mediated signalling is con-
trolled by Glial cell-derived neurotrophic factor family li-
gands (GFLs) and Glial cell-derived neurotrophic factor
receptor alphas (GFRαs), which form a four-member pro-
tein family (GFRα1-4) [14].
Of these, GAS1 has highest (28%) similarity to GFRα1,
while GAS1 and GFRα4 both have only two domains un-
like GFRα1-3, which consists of three domains [15]. The
secondary structure of mammalian GAS1 is predicted to
be mostly α-helical separated by short β-strands and to
have a long unstructured C-terminal domain [15]. By
binding GFLs, GFRαs take part in controlling the survival
of neurons, neuron branching, and functional recovery
[14]. The most studied member of GFLs is GDNF, which
was identified due to its function as a survival factor for
midbrain dopaminergic neurons [14]. GDNF forms a
complex with GFRα1 and promotes the survival of neu-
rons [16]. GFLs, in general, are dimeric proteins and
they are capable of binding two GFRα receptors per lig-
and [14]. After the formation of GFRα-GFL complex,
the complex then binds to the transmembrane tyrosine
kinase RET [16].Figure 1 Purification of recombinant GAS1 from insect cells. A) Ni-affi
from the Ni-affinity chromatography peak at ca. 28 ml. Fractions of 1 ml we
tested in the western blot. C) SDS-PAGE analysis of GAS1 purification (left l
GAS1 after gel filtration; the gel was Coomassie stained.).Despite the structural similarity to GFRαs, GAS1 dif-
fers from them functionally because it is able to bind to
RET in a ligand independent way [8]. In addition, the
intracellular signalling pathway is most probably differ-
ent than for GFRα-GDNF complex, and GAS1 bound to
RET blocks AKT activation, and increases ERK activa-
tion [8].
GAS1 has been suspected to be an ancestor of GFRα
proteins [8,15,17]. Thus the four GFLs and GFRαs could
have been generated by genome duplications at the ori-
gin of vertebrates, and at this point the gene encoding
GAS1 could have diverged from GFRα-like proteins
[17,18].
It has been hypothesised that the relative abundance
and localization of GFRαs, GFLs and GAS1 could deter-
mine in certain conditions whether cells survive or die
[15]. Furthermore, GAS1 expression is increased in neur-
onal cell death during early development [19]. Therefore,
GAS1 could work as a switch between proliferation and
differentiation in neuronal development [8]. GAS1 has
been shown to colocalize to lipid rafts with RET [8]. This
has led to the hypothesis that GAS1 could be a negative
modulator of GDNF signalling and able to control GDNF
stimulation via RET [8,20].Results
Production and purification of human GAS1 protein
After cloning and expressing human GAS1 in Tricoplusia
Ni cells, we purified secreted GAS1 from the insect cell
growth medium using Ni-affinity chromatography (Fig-
ure 1), and the identity and size of the expressed protein
was verified with a western blot (Figure 1). The purified
protein is glycosylated and therefore does not run
exactly according to excepted molecular weight on the
SDS-PAGE, but slightly higher. Thrombin was used to
cleave off the tags, and the size of the protein after
cleavage was verified by SDS-PAGE and MALDI-TOFnity chromatogram for GAS1 purification B) Western blot of fractions
re collected, and fractions from peak area at 23, 27, 29 and 33 ml were
ane, molecular weight marker, with sizes indicated; right lane, purified
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average ca. 1 mg/L.
Based on the primary sequence one N-glycosylation
site was predicted at Asn117 located in the N-terminal
domain. The corresponding site in the GFRα-structures
is located at the domain interface between the two hom-
ologous disulphide rich domains, in a tightly packed
two-domain structure [21,22], suggesting that the GAS1
overall conformation is quite likely very different (see
below, Figure 2).
When the protein was treated with PNGase F to remove
glycans, the size of the protein diminished slightly on SDS-
PAGE (data not shown), and based on MALDI-TOF ana-
lysis, we observe a decrease in molecular weight of ca.Figure 2 Homology modelling of human GAS1 and comparison to GDN
GAS1 N-terminal domain showing different orientations and flexibility of the e
were generated with the Raptor-X server, as mentioned in the text. The temp
N-terminal domain of GFRα1 (dark cyan) and N-terminal domain (GAS1, grey)
involved in heparin and indicated as putative RET binding residues). GFRα1 RE
residues GFRα1 (dark cyan) vs. GAS1 (grey). The GDNF Glu binding to the GFR
lines. A Tyr and Ser residue occupy the positions in GAS1 equivalent to GFRα1
in the figure are shown with stick presentation and atoms S atoms in yellow
of domains D2 and D3. N-glycan at Asn117 of GAS1 is indicated in yellow wit
dark cyan, GAS1 N-terminal domain is drawn in grey.900 Da; the glycosylated protein had a molecular mass of
29.8 kDa and the de-glycosylated protein of 28.9 kDa, ac-
cording to MALDI-TOF, while the theoretical molecular
mass of the protein without glycosylation is 29.0 kD, thus
matching well with the mass spectrometry results. The re-
sult obtained for glycosylated protein corresponds to ap-
proximately one N-glycan added post-translationally in the
insect cells. The purified protein was functional in binding
to RET in vitro, and found to be over 90% pure on SDS-
PAGE, and monodisperse in solution after gel filtration.
GAS1 is a monomer is solution and highly thermostable
The cleaved, non-tagged protein was found to be a mono-
mer by analytical size exclusion chromatography andF receptor structures. A) Four representative homology models of
xtended intradomain loop of higher vertebrate proteins. The models
late for modelling was the GFRα1 structure (PDB: 2VE5). B) comparison to
and RET/heparin binding site (grey residues, GAS, cyan residues, residues
T/heparin binding-site residues are labelled. C) The GDNF binding site
α1 is colored brown, and hydrogen bonds are indicated with dashed
Arg171 and 224, GFRα1 GDNF binding residues are labelled. Disulphides
D) Position of the N-glycosylation site in GAS1 vs. GFRα1 domain interface
h a stick presentation, the GFRα1 D2 and D3 domains are depicted in
Table 1 SAXS-derived size parameters for GAS1
I(0) (Guinier) 25.08
I(0) (Porod) 24.8
Dmax (nm) 10.5
Rg (Guinier/nm) 3.01
Rg (Porod/nm) 3.00
Porod volume (Vp) 54.2
Mw(theoretical) 29 158.3 g/mol
Mw(calc) (Guinier) 25.1 kDa
Mw(calc) (Porod vol.) 31.9 kDa (Vp/1.7)
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1 mg/ml and 4.5 mg/ml the SEC-MALLS runs gave a sin-
gle peak with molecular mass of ca. 31–33 kDa (Figure 3),
matching quite well to the theoretical size of monomeric
GAS1 (29.0 kDa) considering the additional glycosylation
at one site. Similarly, based on the small-angle X-ray scat-
tering (SAXS) data, the molecular weight matches most
closely to a monomer (Table 1). In our opinion, this is
likely to reflect the oligomerization state of the lipid-
anchored protein, which is unlikely to be affected by the
anchor. No detectable oligomerization was observed in
native PAGE or gel filtration at 4.5 mg/ml, while in SAXSA
B
C
Figure 3 GAS1 analytical gel filtration, circular dichroism and
thermal unfolding. A) GAS1 sample was run on Superdex 200 10/300
gel filtration column in TBS at 0.5 ml/min, at protein concentration of
1 mg/ml. A single major peak at 30 min (X-axis) eluted and based on
multi-angle light scattering had molecular weight (right Y-axis) of ca.
33 kDa, matching relatively well with theoretical molecular weight of
the monomer. The peak is plotted as a function of dRI signal (left Y-axis).
B) The CD spectrum of GAS1 and C) the residual thermal denaturation
of GAS1 as monitored by CD at 222 nm.
The Guinier I(0)-value was calculated against an absolute reference (scattering
of water relative to sample) [23] and the I(0) for the sample is then equal to
the molecular weight. Molecular weight from the Porod volume is estimated
according to Petoukhov et al. [24].data an effect from residual aggregation was evident at
higher concentrations.
Circular dichroism (CD) spectroscopy was used to ver-
ify the secondary structure content of GAS1 and, as ex-
pected, the CD spectrum was typical for an α-helical
protein (Figure 3). A measured temperature denatur-
ation curve with CD gave a result with partial melting of
the structure when heated to 90°C (Figure 3). However,
full temperature denaturation was not possible to obtain
by CD, nor by differential scanning calorimetry (data not
shown), possibly due to the high disulphide content of
the protein. This suggests that the domain structure is
thermally very stable. The decrease in CD signal at
222 nm did not even reach the midpoint of denaturation
when heated to 90°C (Figure 3).
Sequence analysis and evolution of GAS1
The GAS1 protein domain structure is defined by two
GFRα–like domains, with 10 conserved disulphide bridge-
forming cysteines in each domain [25]. GAS1 is present in
all the vertebrates, and homologs are also found in lower
chordates (e.g. Ciona and Amphioxus [17]). In addition,
GAS1 homologs also occur in C. elegans and honeybee,
but not, surprisingly, in Drosophila. The sequence identity
to vertebrate proteins, however, is quite low: ca. 21-24%
for honeybee and only 14-19% for the worm sequence
(Table 2). Two conserved cysteines are missing from the
C. elegans sequence (Figure 4), and thus the protein fold
might not be fully conserved in the C. elegans homolog
(phas-1) [26]. Alignment of the GAS1 sequences shows
that, in higher vertebrates, the N-terminal domain has an
insertion with low sequence complexity (Figure 4), appar-
ently forming an extended loop structure (Figure 2).
Mammals have also an RGD sequence in the C-terminal
linker region. Also, a single N-glycosylation site at Asn117
is predicted to be conserved based on sequence in all ver-
tebrates, while it is not present in the invertebrates. In the
set of conserved residues beyond the structural cysteines
Table 2 Amino acid sequence identities (%) within the GAS1 protein family
Human Sus
scrofa
Bos
Taurus
Canis
Lupus
Mouse Gallus
gallus
Alligator Anolis Xenopus Latimeria Danio
rerio
Apis C. elegans
Human 100
Sus scrofa 95.3 100
Bos Taurus 94.1 94.4 100
Canis Lupus 91.1 91.4 90.2 100
Mouse 85.4 85.4 84.9 82.9 100
Gallus gallus 61.9 61.7 60.1 62.1 59.6 100
Alligator 60.3 60.7 59.9 59.9 60.1 70.9 100
Anolis 55.8 56.2 54.5 57 55.7 54.7 57.6 100
Xenopus 51.2 51.7 50.8 50.6 50.5 52.2 55 48.4 100
Latimeria 47.2 47.4 46.6 46.3 45.9 48.4 50.5 42.1 49 100
Danio rerio 35.2 34.5 35 35.6 35.8 37 38.7 34.2 37.6 43.4 100
Apis 22.1 21.7 21.3 21.6 21.1 23.1 23.7 22.6 22.1 22.8 23.7 100
C.elegans 15.6 15.6 14.6 15.5 14.3 14.7 15.9 14.2 19 17.8 17.1 15.4 100
Pairwise identities between species that are over 70% are shown in bold.
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Glu) (Figure 4) a subset are present only in the vertebrate
proteins, and, other than the conserved cysteines, only ten
residues are conserved also in C. elegans.
When the conserved amino acid residues are displayed
onto the surface of the modelled domains, the most con-
served surface patch is found on the N-terminal domain
surface formed by residues on helices 3–5, whereas the
C-terminal domain surface did not reveal large patches
of conservation (Figure 4). Here conservation is defined
by >75% sequence similarity amongst the residue groups
KHR, ED, NQSTGP, ILMVCA and FYW.
Homology modelling of GAS1 domains and comparison
to GFRαs
We constructed homology models of both GAS1 do-
mains with the RaptorX-server (http://raptorx.uchicago.
edu/) [27], designed for low sequence homology-based
modelling. The models for both domains fit well to the
GFRα-structure (PDB: 2VE5) [22]. As described above,
the N-terminal domain of mammalian GAS1-proteins
contain a large inserted loop with low sequence com-
plexity, which based on modelling indeed appears to
form a large flexible loop, but whether this region has
functional significance or not remains unclear.
Modelling of GAS1 has partially been done before also
by Cabrera et al. [8] and Schueler-Furman et al. [15].
Here our aim was to study possible conservation of the
ligand binding regions of GFRαs vs. GAS1, to do more
detailed analysis on the structure, and to provide models
for the analysis of SAXS data (see below).
Although the sequence identity to the related GFRα
structures is low, the cysteines involved in disulphide
bridges are well conserved for the two GFRα-typedomains and make structure prediction possible. The N-
terminal domain of GAS1 is equivalent of the second
domain in GFRαs, which contains the growth factor
binding site. We aligned our model of GAS1 with the
GFRα1:GDNF complex structure [22], and, based on the
structural alignment, the binding region for the GDNF is
not conserved in GAS1 (Figure 2). Similarly the con-
served binding residues in GFRα2:Artemin complex
(PDB: 2GH0) [21], are not present in GAS1. In fact, the
key ionic residues required for ligand binding are con-
served in both these structure, but not present in GAS1.
The conserved key residues for GDNF binding in GFRα1
are Arg171, Arg224 and Asn162. In our structural ana-
lysis GAS1 has Tyr26, Thr100, Gln17 in equivalent side
chain positions; in GAS1, the ion triplet required for
growth factor binding [22] is absent.
It has also been suggested by Wang et al. [21] and
Parkash et al. [22] that a RET binding region would be
located mostly in the second (“D2”) domain on the GFRαs
and would involve the GFRα1 residues Arg190, Lys194,
Arg197, Gln198, Lys202, Arg257, Arg259, Glu323, and
Asp324. This site forms a highly positively charged
patch on the surface of GFRα1, identified also as a hep-
arin binding site by Parkash et al. [22]. We analysed the
equivalent region in the N-terminal domain of GAS1,
but found no conservation between the GFRα1 structure
and GAS1 (Figure 2). Overall GAS1 is not positively
charged, as would be expected of a typical heparin-binding
molecule. The calculated pI-value for human GAS1 is 5.0
whereas for human GFRαs the values range from 7.5-7.6
(GFRα2 − 3) to 8.4 (GFRα1) and 10.1 (GFRα4). Also, GAS1
does not contain a highly positively charged patch in the
suggested RET/heparin binding region, and heparin affinity
chromatography of GAS1 showed no significant binding to
Figure 4 The GAS1 family sequence alignment. A) The sequences
start from the beginning of the mature human GAS1 and numbered
according to the human amino acid numbering. Residues over ca.
85% conserved (11/13) are coloured with a black-to-grey scale, in
higher vertebrates (mammals) there is an extended loop in the N-
terminal domain around residues 80–100 (human GAS1 numbering).
The C-termini are poorly conserved (residues beyond 250), note the
RGD sequence at 306–308. B) Conserved surface features on GAS1
displayed on the N-terminal domain. C) Conserved surface features on
GAS1 displayed on the C-terminal domain; conserved sites in B and C
are coloured in red (with >75% sequence similarity, see text).
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binding protein HBGAM eluted only at 1 M NaCl
(Figure 5). Finally, modelling of GAS1 N- terminal do-
main shows that glycosylated Asn117 will be situated at
the position equivalent to the domain interface between
domains D2 and D3 in the GFRα structures (Figure 2).
Structural characterization of GAS-1 by solution X-ray
scattering
Solution X-ray scattering (SAXS) data indicated that
GAS1 is monomeric at 0.8 mg/ml in solution based on
the Porod volume and Guinier plots (Table 1): at higher
concentrations the protein starts to aggregate, and the
data beyond 1 mg/ml could not be analysed. Rigid body
modelling of the structure was done based on homology
models of the individual domains, and elongated models
gave the best fits (Figure 6). We also calculated ab initio
envelopes, which matched well with rigid body model-
ling of the structure (Figure 6). Both differ significantly
from the compact GDNF co-receptor structures [21,22].
However, as it is clear that the structure is likely to be
flexible, in particular the C-terminal long unstructured
region, we also did ensemble fitting of the model against
the data. This resulted in a bimodal ensemble repre-
sented by four major structures selected from the initial
random pool of 10 000 structures, which fit to the data
with χ2 = 0.84 (Figure 6). The selected structures repre-
sent states with extended and collapsed C-terminal
linkers and variable orientations of the domains relative
to each other (Figure 6). Taken together it appears from
the SAXS data that the orientation of the domains of
GAS1 relative to each other is not fixed; clearly the pro-
tein exists in two populations of extended and collapsed
conformations.
Binding and affinity of GAS1 to RET in vitro
We tested whether GAS1 is able to directly interact with
RET in a ligand independent way, as previously reported
[8]. For this purpose, and to determine the affinity of the
interaction, the RET receptor was coupled to a chip for
surface plasmon resonance assay, and binding of a con-
centration series of GAS1 to immobilized RET was mea-
sured. A Kd-value of 12.2 ± 8.2 μM was measured for the
Figure 5 Heparin affinity chromatography of GAS1. A) Elution of GAS1 as a function of salt concentration. B) Elution of HBGAM as a function of
salt concentration. Chromatograms are plotted with absorbance in mAU unit (right y-axis) and salt concentration gradient to 1 M NaCl (%) (left y-axis),
against volume in ml.
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action were too fast to allow for measurement of on-
and off-rates, as is evident from the time scale of the
binding and dissociation from the sensograms (Figure 7).
Discussion
We have overexpressed and purified the human GAS1
protein in soluble form without the GPI-anchor, and
biophysically characterized the protein. We constructed
homology models for both domains of GAS1 and were
able to analyse the domain structure of the protein in
comparison to the structurally related GFRαs. As re-
ported earlier by others [8], GAS1 has clearly two
GFRα-like domains, but we have shown here that GAS1
differs significantly from GFRαs in both sequence and in
structure.
The differences can be characterized as follows: Firstly,
GAS1 has a large, 10–15 amino acid unstructured, low
complexity Ala/Gly/Pro-containing loop in the N-
terminal domain. This loop region is present in higher
vertebrates, in mammalians and chicken, but not in fish
(Figure 4). Whether this loop might have some function
remains unknown. Secondly, the two-domain structure
of GAS1 appears to be more flexible overall than in the
characterized GFRα structures. In the GFRαs, the func-
tional domains D2 and D3 form a compact structure,
whereas GAS1 SAXS analysis reveals a flexible ensemble
of structures, with the N- and C-terminal domains as in-
dependent structural units. This might reflect the loca-
tion of the functional binding regions of the molecule
versus those of the GFRαs. As expected, the protein is α-
helical based on the CD spectrum. It is somewhat intri-
guing that we were not able to fully denature the
protein; apparently the disulphide-linked arrangement of
the domains is highly thermostable, and this might be a
general feature of the GFRα-family.
The structural flexibility is probably a conserved fea-
ture in the protein family, as the single N-glycosylation
site in the human protein is conserved in chordates. This
N-glycan blocks the GFRα-equivalent domain interface,and hence the formation of that type of compact struc-
ture. It has been also observed that this glycosylation site
might have functional significance for SHH binding [28].
Our sequence analysis and that by Hätinen et al. [17]
suggest that GAS1 is conserved during evolution, with
homologs in chordates (from Ciona and Amphioxus), ar-
thropods and roundworms, thus possibly representing
an ancestral GFRα-like protein [17] However, the se-
quence identity from chordate to invertebrates (e.g.
honey bee and C. elegans) genes is low, 14-19% for the
worm phas-1 homolog of GAS1 [26], and it remains an
open question whether the insect or worm genes identi-
fied as GAS1 actually share any of the functions of ver-
tebrate GAS1/GFRα type of receptors, either in RET or
the hedgehog signalling.
GAS1, as well as GFRα-like proteins, are conserved
beyond vertebrates, while GFLs are not expressed in
non-vertebrates. This suggests that either RET binding,
independent of GFLs is conserved, or that there are al-
ternative receptors for GAS1. In case of GAS1, this
could be SHH and patched-1. Interestingly in Drosoph-
ila, the GRFα-like protein does not interact with RET
but does interact with Drosophila NCAM analog, FasII
[29]. The mammalian GFLs are known to be ligands of
NCAM [30]: whether GAS1 might interact with NCAM
homologs remains to be investigated.
When we compared our model with the GFRα1 struc-
ture it was clear that the crucial amino acids for GFL
binding are not conserved in GAS1, and it most likely
lacks the ability to bind GFL-like ligands, as they all
share the same binding mode [21,22]. Indeed Cabrera
et al. [8] reported that GAS1 is not able to bind GDNF.
While GAS1 lacks the ability to bind GFL-type of li-
gands, our in vitro binding data support the findings by
Cabrera et al. [8] that GAS1 can bind RET in a ligand
independent manner, and possibly alter the intracellular
signalling of RET.
The affinity of GAS1 for RET is significantly lower
than that of the GFRα-GDNF ligand complex in solution
(Kd = 12.2 μM versus 0.2 nM for GFRα1-GDNF binding
Figure 6 Rigid body and ab initio modelling of GAS1 based on SAXS data. A) Scattering curve and fit of CORAL rigid body model (red line) to
observed data. B) The Kratky-plot from the experimental data, suggesting a folded structure with some flexibility. C) CORAL generated model with N- and
C-terminal domains as rigid bodies (blue) with flexible linker regions (grey beads; left), and the ab initio model for GAS1 generated by DAMMIN (green;
average of 10 calculations) fitted over the rigid body model (right). D) The distance distribution calculated for GAS1 SAXS data. E) SAXS ensemble
modelling of GAS1 solution conformations shown as the statistical distribution of Rg-values of best fitted models (continuous line with closed circles) vs.
initial random pool (dashed line with open circles) shows a bimodal distribution of GAS1 solution conformations. F) The selected pdb-files representing
the ensemble with Chi2 = 0.84 fit to the experimental data, showing extended (blue) and more collapsed models (yellow, red, cyan) in the final ensemble;
the N-terminal domain (in grey) was fixed relative to the rest of the protein during the runs. The modelled glycan structure is shown as red “stick”
presentation on the N-terminal domain.
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GAS1 to RET is also likely to be higher as the diffusion
is restricted to two-dimensions.
Another possibility is that in some cellular contexts
GAS1 would be highly expressed on cell surface, which
might boost the binding to RET locally. The exact mech-
anism of GAS1 on RET signalling remains elusive, but it
seems clear that GAS1 has an effect of RET signalling,
probably by inhibiting growth-factor dependent signal-
ling [4,8].
Based on the conservation of protein surface features,
as mapped on to the GAS1 models, we suggest that the
N-terminal domain region defined by α − helices 3–5might contain a functional binding site (Figure 4),
whereas other possible interaction surfaces remain less
clear, e.g. the very short RGD-peptide motif found in
mammalian sequences could be functional, or exist by
chance, and so far no biochemical evidence for the func-
tion exists.
GAS1 has also been reported to alter SHH-signalling
through patched-1 [28,33], indicating that GAS1 has
multiple functions. Related to this Pineda-Alvarez et al.
[34] and Ribeiro et al. [35] reported missense mutations
of GAS1 in holoprosencephaly (HPE) patients.In par-
ticular Thr200Arg mutation in the second domain of
GAS1 Pineda-Alvarez et al. [34] was observed to result
AB
Figure 7 Binding of human GAS1 to RET. A) A binding curve of
GAS1 to ecRET. Purified human GAS1 shows clear ligand
independent binding to ecRET. Binding was measured with a
concentration series of 2 μM, 4 μM, 8 μM and 16 μM, 24 μM and
32 μM. The dissociation constant (Kd) was obtained based on the
equilibrium (Req) values at different concentration from two
independent experiments with a Kd = 12.2 ± 8.2. B) The biacore
sensograms for GAS1 binding (in response units, RU) to RET at
different concentrations (as above).
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hence this domain could also be important for binding
to SHH. Also Asn220Lys caused 20% reduction in bind-
ing according to Pineda-Alvarez et al. [34] and Ala246-
Ser patient mutations are located in the same domain,
while the mutations are some what scattered around the
domain and do not cluster together on the surface.
Conclusions
Our structural data reveal that GAS1 is a flexible two-
domain molecule, the flexibility perhaps reflecting its
multifunctional properties. The structural arrangement
of the domains is clearly different form the compact
GFRα structures, suggesting that it has different func-
tional roles. In particular, neither the putative heparan
sulphate proteoglycan/RET binding site [22] the known
growth factor binding site are conserved in GAS1.Thus, GAS1 must act on RET in a different way, and
together with previous analysis our binding data sup-
ports the ligand-independent RET binding by GAS1,
while sequence conservation analysis hints at possible
sites of functional importance.
Methods
Ethics statement
All results of this research were based proteins expressed
in cultured Tricoplusia Ni or Spodoptera frugiperda cells
lines. Neither human (human subjects, human material
or human data) nor animals (vertebrates or any regu-
lated invertebrates) were used in this experimental
research.
Plasmids, reagents and cell lines
Human GAS cDNA1 in a pCR3.1 plasmid was obtained
as kind gift from Prof. Mart Saarma, and the pFastBac
(Invitrogen) derivative vector pK509.3 from Prof. Kari
Keinänen [36]. Oligonucleotides were purchased from
Sigma and Phusion polymerase and PCR reagents were
from Finnzymes Inc., E.coli DH10Bac-cells, Tricoplusia
Ni and Spodoptera Frugiperda insect cells were from
Invitrogen. Serum Free insect cell culture media was
purchased from HyClone, gentamycin from Dushefa.
Baculovirus production was done according to Bac-to-Bac
manual (Invitrogen). SDS-PAGE gels were bought from
Bio-Rad. The anti-FLAG monoclonal M1 mouse antibody
was from Sigma, the anti-mouse antibody from Santa
Cruz biotechnology, 5 ml HisTrap crude Ni-NTA column,
size exclusion column Superdex 10/300, and Thrombin
protease, 3 M HyBond western-blot membrane, and the
ECL reagent were all from GE Healthcare.
PCR and cloning
Human GAS1 cDNA in pCR3.1 plasmid was used as a
template for PCR. The region encoding amino acids 39–
317 was amplified, thus omitting the part encoding the
native secretion signal at the N-terminus and the pre-
dicted GPI-anchor in the C-terminus. The PCR product
was subcloned between Not1-Hind III restriction sites to
baculovirus pFastBac-derivative vector pK509.3, which
has the honey bee mellitin secretion signal and a Flag-
tag sequence upstream of the cloning site.
The forward PCR primer was designed to add additional
amino acids at the N-terminus for a His6-tag and a Throm-
bin protease cleavage site (LRPHHHHHHLVPRGS).
The PCR primer sequences used for cloning were: 5′
ACTTAACTGCGGCCGCATCATCACCATCACCATC
TTGTTCCTCGTGGTTCTGCGCACGGCCGCCGCCT
CATC-3′ (forward) and 5′-AGATCTTAAGCTTACCT
GCGCCCAGGCCCATAG-3′ (reverse). The template
was PCR amplified with 5% DMSO to optimize it for a
high GC-rich template (here, 81.2 %). PCR cycling
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(Finnzymes Inc). Cleaved and agarose gel purified vector
and insert were ligated using T4 ligase (New England
Biolabs).
Virus propagation and Western-blots
The GAS1 construct was transformed to DH10Bac-cells to
transpose it as a part of baculovirus shuttle-vector. The
resulting DNA was isolated as described in the Bac-to-Bac
manual (Invitrogen). Baculoviruses were multiplied by
transfecting Sf9 cells on Cellstar (GreinerBio-one) six-well
plate at 70 % confluency according to the manufacturer’s
instructions (Mirus. USA). In short, 200 μl of serum free
HyQ-SFX medium, lacking antibiotics, were placed in
microcentrifuge tubes with 6 microliters of TransIt re-
agent (Mirus), and incubated 20 minutes at room
temperature. Two micrograms of bacmid DNA was
added to the reactions and incubation was continued
for another 20 minutes. Cells were washed with phos-
phate buffered saline (PBS) pH 7.4, and the medium
changed to fresh HyQ-SFX. The transfection mixture
was then added to the cells drop-wise. Cells were incu-
bated at +27°C for five hours, after which the medium
was changed to serum free SFX medium supplemented
with 50 μg/ml Gentamycin. Cells were incubated for
five days. The virus production efficacy was estimated
by comparing the wells with non-infected control wells;
properly infected cells stopped dividing, grew in size,
and finally lysed. Virus was passaged typically by infect-
ing 70-90% confluent plates. Passage one was done by
adding 2 ml of virus from transfected cells to 70% con-
fluent plate, in a total culture volume of 5 ml. For pas-
sages two and three, 90 % confluent plates were made
by infecting cells with three to four millilitres of virus
from the previous passage in a total volume of 25 ml.
Virus propagation was estimated by visual analysis, as
described, and by detecting the presence of the flag-
tagged GAS1 protein by western blot. Virus propaga-
tion was typically continued to at least passage four, in
order to get sufficient amount of virus to infect the cul-
ture used for protein production.
Protein production and purification
The GAS1 protein was produced by infecting 200 ml of
Tn5 cells, typically at 2 × 10 6 cell density, with 5 ml of
high titer virus, typically from passage three or four.
72 h post infection the cells were harvested by centrifu-
gation and the supernatant was collected.
The secreted GAS1 protein was purified from the
supernatant by Ni-affinity chromatography. The column
was equilibrated with binding buffer containing 20 mM
sodium phosphate pH 7.4, 150 mM sodium chloride and
5 mM imidazole, and the protein was eluted with linear
5–500 mM imidazole gradient with the binding buffer.GAS1 protein was detected by SDS-PAGE and identity
confirmed by a FLAG-tag Western blot; based on this
1 ml fractions from the peak area were collected
(Figure 1).
GAS1 protein containing fractions were detected from
the major peak. These pooled and concentrated with a
30 kDa cut-off Amicon spin concentrator (Millipore) for
4000 rpm at +4°C, typically up to 500 μl volume. The buf-
fer was exchanged, to phosphate buffered saline (PBS),
pH 7.4, by diluting to 15 ml and repeating the centrifuga-
tion step as described.
After buffer exchange, the tags were cleaved off with
Thrombin protease at a ratio of ten units per milligram
of protein, the cleaved protein was concentrated to a
350 ul final volume, and further purified using size ex-
clusion chromatography with Superdex 10/300 GL col-
umn in a buffer containing Tris-buffered saline (TBS)
pH 7.4, (25 mM Tris pH 7.4; 150 mM NaCl; 2 mM
KCl, pH adjusted with HCl), supplemented with 250 mM
NaCl at a 0.5 ml/min flow rate. Fractions of 2 ml were col-
lected and analyzed by SDS-PAGE. The fractions contain-
ing correct, approximately 35 kDa protein were pooled
and concentrated as previously described.Surface plasmon resonance assay
Surface plasmon resonance (Biacore™, GE Healthcare)
was used to determine the binding affinity of GAS1 pro-
tein to the ectodomain of RET protein (ecRET; R&D
Systems, catalog no. 1168-CR-050/CF).
For this purpose ecRET was coupled to a CM5 chip
(GE Healthcare) by amide coupling. The chip was
ctivated according to manufacturers instructions with 1-
ethyl-3-(3-dimethylaminopropyl carbodiimine (EDC)- N-
hydroxysuccimide-(NHS) solution (Amine coupling kit,
GE Healthcare). The ecRET at 0.25 mg/ml in PBS was di-
luted 1:10 to 10 mM Na-acetate,pH 5.0 and coupled to
the chip at 4000 RU level.
After ecRET was coupled to the chip, the remaining
free activated carboxyl groups on the surface were inac-
tivated with 1 M ethanolamine (GE Healthtcare). The
buffer used for binding experiment was 10 mM Hepes
pH 7.4, 150 mM NaCl (HBS) supplemented with 1 mM
CaCl2, 0.01% Triton X-100. First flow channel from the
chip was used as a blank control channel showing the
possible non-specific binding to a non-coated surface. A
GAS1 sample concentration series from 2 μM to 32 μM
was injected at 20 ul/min for 2 minutes, and after each
experiment the chip surface was regenerated with 1 M
MgCl2 with two 10 μl injections to release the bound
GAS1 from RET. The dissociation constant for GAS1 to
RET binding was calculated from binding curve calcu-
lated fitted from the equilibrium response (Req) values
for binding at each concentration (Figure 7).
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light scattering
The GAS1 protein ab initio solution structure was ob-
tained with 0.8 mg/ml protein in 50 mM Tris pH 7.5,
50 mM NaCl buffer. Small-Angle-X-Ray scattering data
collection (ESFR, France) was performed with 1 s expos-
ure time per image, and 10 repeats per sample, and
these averaged and subtracted from similarly averaged
buffer baseline. The measured data was analysed using
PRIMUS [37] software and the ab initio modelling of
the protein was done by DAMMIF/DAMAVER software
[38]. The model of the protein with flexible linkers was
obtained by using rigid body homology modelling
against collected data. Original homology modelling of
the domains to GFRα1 was done with Raptor-X server
and rigid body modelling of the two-domain structure
and modelling of flexible linkers was done with CORAL
and BUNCH within the ATSAS software package [39].
Ensemble modelling of SAXS data was done using EOM
2.0 [38,40] via the ATSAS-online server (http://www.
embl-hamburg.de/biosaxs/atsas-online/).Multi-angle laser light scattering
SEC-MALLS measurements were run at 0.5 ml/min over
an S-200 Superdex 10/300 column (GE Healtcare) in
20 mM TRIS pH 7.4, 150 mM NaCl with a Schimadzu
HPLC system and MiniDAWN TREOS light scattering
detector and Optilab rEX refractive index detector (Wy-
att Technology Corporation). Data was analysed with
ASTRA 6 software (Wyatt Technology Corporation).Circular Dichroism and thermal stability
Circular Dichoism (CD) spectrum at 190–260 nm was
collected on a JASCO J-720 instrument. For this experi-
ment the protein was dialyzed against 20 mM Na phos-
phate pH 7.4, 50 mM NaCl. The GAS1 sample was
diluted to 6.5 μM concentration in the same buffer.
Measurement was done with a capped 350 μl 1 mm light
path quartz cuvette (Hellma-Analytics). Data for thermal
denatural analysis was collected at 222 mm wavelength
from 20 to 90°C, with one degree steps and 30 second
incubation at each temperature.
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